INT155216

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.56
First Reported 2005
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 9
Total Number 9
Disease Relevance 3.81
Pain Relevance 2.71

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

small molecule metabolic process (CYP3A4) oxidoreductase activity (CYP3A4) endoplasmic reticulum (CYP3A4)
enzyme binding (CYP3A4) lipid metabolic process (CYP3A4) cytoplasm (CYP3A4)
Anatomy Link Frequency
plasma 4
liver 2
CYP3A4 (Homo sapiens)
Pain Link Frequency Relevance Heat
Duloxetine 84 99.80 Very High Very High Very High
ketamine 12 99.18 Very High Very High Very High
cytokine 5 99.06 Very High Very High Very High
Inflammation 3 98.46 Very High Very High Very High
antagonist 22 97.96 Very High Very High Very High
carbamazepine 20 96.92 Very High Very High Very High
Buprenorphine 159 95.08 Very High Very High Very High
Endep 1 94.68 High High
Nortriptyline 1 94.08 High High
rapifen 8 93.48 High High
Disease Link Frequency Relevance Heat
Cirrhosis 39 99.40 Very High Very High Very High
Liver Disease 4 98.68 Very High Very High Very High
INFLAMMATION 4 98.46 Very High Very High Very High
Myocardial Infarction 58 93.24 High High
Injury 9 92.76 High High
Sudden Death 1 90.88 High High
Hypoalbuminemia 3 88.88 High High
Partial Seizures 59 86.32 High High
Gallstones 19 85.84 High High
Disease 13 85.04 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Consequently, ketamine-caused cytoskeletal interruption led to suppression of CYP3A4 expression and its metabolizing activity.
Negative_regulation (suppression) of Gene_expression (expression) of CYP3A4 associated with ketamine
1) Confidence 0.56 Published 2009 Journal Drug Metab. Dispos. Section Abstract Doc Link 18845661 Disease Relevance 0.14 Pain Relevance 0.53
Factors affecting the clinical outcomes of mechanism-based CYP3A4 inhibition
Negative_regulation (based) of Gene_expression (inhibition) of CYP3A4
2) Confidence 0.43 Published 2005 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1661603 Disease Relevance 0.26 Pain Relevance 0.12
The expression of CYP3A can also be influenced by inflammation and proinflammatory cytokines, which are known to affect drug metabolism by downregulating or upregulating expression of several CYPs, including the CYP3A subfamily.
Negative_regulation (downregulating) of Gene_expression (expression) of CYP3A associated with inflammation and cytokine
3) Confidence 0.43 Published 2005 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1661603 Disease Relevance 0.30 Pain Relevance 0.19
The impaired expression of hepatic proteins including CYP3A4 might affect the metabolism of endogenous cortisol into its metabolite; 6 ?
Negative_regulation (impaired) of Gene_expression (expression) of CYP3A4
4) Confidence 0.39 Published 2006 Journal Biomark Insights Section Body Doc Link PMC2716776 Disease Relevance 0.96 Pain Relevance 0.03
Grapefruit inhibits CYP3A4, a P450 isozyme important in the metabolism of some of the benzodiazepines, CBZ, TGB, and ZNS.54
Negative_regulation (inhibits) of Gene_expression (Grapefruit) of CYP3A4 associated with carbamazepine
5) Confidence 0.19 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2898168 Disease Relevance 0.56 Pain Relevance 0.05
Of clinical relevance, duloxetine does not inhibit or induce the CYP3A4 system, but administration of CYP1A2 inhibitors may result in elevated duloxetine concentrations.42 The CYP1A2 inhibitor thioridazine should not be coadministered with duloxetine due to the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated plasma levels of thioridazine.39 Adverse effects on the fetus have been found in animal reproductive studies, rendering duloxetine a Category C agent for women who are pregnant.42
Negative_regulation (inhibit) of Gene_expression (system) of CYP3A4 in plasma associated with duloxetine and sudden death
6) Confidence 0.18 Published 2010 Journal Journal of pain research Section Body Doc Link PMC3004640 Disease Relevance 0.53 Pain Relevance 0.72
Since CYP3A4 protein expression is reduced in patients with severe chronic liver disease, patients with this condition should be closely monitored during treatment (Tegeder et al 1999).


Negative_regulation (reduced) of Gene_expression (expression) of CYP3A4 in liver associated with liver disease
7) Confidence 0.14 Published 2006 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1661652 Disease Relevance 0.78 Pain Relevance 0.96
While conivaptan is metabolized by cytochrome P450 3A4 (CYP3A4), the drug is also a potent inhibitor of CYP3A4.
Negative_regulation (inhibitor) of Gene_expression (metabolized) of CYP3A4
8) Confidence 0.06 Published 2008 Journal Core Evidence Section Body Doc Link PMC2899804 Disease Relevance 0.29 Pain Relevance 0.08
Concomitant administration of DNG and CYP3A4 inducers may result in elevated DNG clearance rates.3 Concurrent treatments with CYP3A4 inhibitors may elevate plasma DNG concentration.3
Negative_regulation (administration) of Gene_expression (inducers) of CYP3A4 in plasma
9) Confidence 0.05 Published 2010 Journal International Journal of Women's Health Section Body Doc Link PMC2990895 Disease Relevance 0 Pain Relevance 0.04

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox